Unapproved Peptides and Safety in Australia

The short answer

In Australia, a therapeutic good is described as approved when it is entered on the Australian Register of Therapeutic Goods, known as the ARTG. A substance that is not on the ARTG is referred to as unapproved. Many peptides sold for laboratory or research purposes are not on the ARTG, which means the Therapeutic Goods Administration, or TGA, has not assessed them for quality, safety or efficacy in the way it assesses registered medicines.

Because that assessment has not taken place, unapproved peptides carry regulatory and quality uncertainty. This article explains the framework in neutral terms, including the role of the ARTG, the Poisons Standard, and the research-use-only designation. It does not provide dosing, protocols or health advice of any kind.

What approved means: the ARTG

The ARTG is the public database of therapeutic goods that may be lawfully supplied in Australia. When a medicine is registered or listed, it receives an ARTG number, and that number generally appears on the labelling and packaging. Entry on the register follows an evaluation by the TGA under the Therapeutic Goods Act 1989.

For registered prescription medicines, that evaluation considers quality, safety and efficacy. The presence of an ARTG number does not mean the TGA endorses or promotes the product. It simply indicates that the good has been through the relevant assessment pathway and is authorised for supply.

What ARTG entry typically signals

• The good has been assessed under the Therapeutic Goods Act 1989.
• An ARTG number has been issued and generally appears on labelling.
• The product may be lawfully supplied in Australia within its approved conditions.
• For registered prescription medicines, quality, safety and efficacy have been evaluated.

What unapproved means

A therapeutic good that is not on the ARTG is an unapproved good. For these goods, the TGA has not evaluated quality, safety, efficacy or performance, so the usual regulatory oversight that applies to registered medicines is not present.

Unapproved does not always mean there is no scientific interest in a substance. In a clinical context, unapproved therapeutic goods can sometimes be accessed through specific regulated pathways overseen by the TGA, such as clinical trials or authorised access arrangements managed by health professionals. Those pathways are separate from the general consumer market and are controlled by the regulator.

The key point for this explainer is that when a peptide is unapproved, buyers cannot rely on a TGA assessment of its quality or identity. That gap is the source of much of the uncertainty discussed below.

The Poisons Standard and scheduling

Alongside the ARTG, Australia uses the Poisons Standard, formally the Standard for the Uniform Scheduling of Medicines and Poisons, often shortened to SUSMP. It is a legislative instrument that classifies substances into schedules according to the level of control considered appropriate for their access.

Schedule 4 of the Poisons Standard covers Prescription Only Medicines. Scheduling is generally decided substance by substance, so the correct way to check any particular peptide is against the current Poisons Standard rather than by assuming a blanket rule. A number of peptide substances fall within Schedule 4, which means that, where they are intended for human therapeutic use, they would ordinarily require a prescription from an authorised health practitioner.

It is possible for a substance to be captured by a schedule while also not being on the ARTG. In other words, scheduling and ARTG registration are two different questions, and a peptide can be both unapproved for supply as a medicine and scheduled as prescription only.

Research use only as a designation

Research use only, often abbreviated to RUO, is a labelling designation used for products intended for laboratory research and not for human or veterinary use. An RUO label signals that the material is supplied for research purposes and has not been presented, assessed or authorised as a medicine.

Because an RUO product is not being supplied as a therapeutic good for people, it is not accompanied by the assurances that attach to a registered medicine. The designation describes the intended use of the material. It does not by itself make any claim about therapeutic benefit, and it does not place the product on the ARTG.

NovaPeptides supplies products on a research-use-only basis. That positioning reflects the distinction set out in this article: research materials are a separate category from approved medicines, and nothing on this page should be read as encouraging human use.

Why unapproved substances carry quality uncertainty

When a product has not been assessed by the TGA, there is no regulatory confirmation of what it contains, how pure it is, or how consistently it has been manufactured. This is why unapproved substances are described as carrying identity, purity and quality uncertainty. The actual content of a vial cannot be assumed from its label alone.

Sources of uncertainty with unapproved material

• Identity: whether the substance is what the label states.
• Purity: the presence or absence of impurities or by-products.
• Concentration: whether the stated quantity matches the actual content.
• Consistency: whether manufacturing is uniform from batch to batch.
• Stability: how storage and handling affect the material over time.

In research settings, independent analytical testing is commonly used to address some of these questions. A Certificate of Analysis, or CoA, is a document from a laboratory that reports testing results for a given batch, such as identity and purity measures. Third-party or independent laboratory testing provides an external check on what a batch contains. A CoA is a quality-control record for research purposes. It is not a TGA assessment, and it does not approve a substance for human use or imply any health benefit.

An unapproved substance has not been evaluated by the TGA for quality, safety or efficacy, so independent documentation becomes the main available reference point in a research context.

Advertising rules in Australia

Australian law places strict limits on how therapeutic goods may be promoted. Prescription-only medicines and unapproved therapeutic goods cannot be advertised to the public with therapeutic claims. This means that statements suggesting a substance treats, prevents or manages a health condition are not permitted for these goods in consumer advertising.

Advertisers also cannot use phrases such as TGA approved or TGA registered to promote a product, although a legitimate ARTG number may be cited where one exists. For a research-use-only supplier, the practical effect is that product information stays factual and avoids any claim of human benefit, because such claims would be both non-compliant and inconsistent with the research-only positioning.

General advertising principles for these goods

• No therapeutic or efficacy claims for prescription-only or unapproved goods in public advertising.
• No use of TGA approved or TGA registered as a promotional phrase.
• Factual, research-oriented information only, with no human use implied.
• Claims about a substance should never outrun what the evidence and the law allow.

What this means for research contexts

Pulling the threads together, the Australian framework draws a clear line between approved medicines on the ARTG and everything else. Peptides that are not on the register are unapproved, may also be scheduled as prescription only, and have not been assessed by the TGA for quality, safety or efficacy. That combination is the reason unapproved peptides are described as carrying regulatory and quality uncertainty.

For anyone working with research materials, the sensible posture is to treat regulatory status as a question to be checked against current TGA sources, to value independent documentation such as a Certificate of Analysis as a quality-control record, and to keep research materials firmly separate from any idea of human use. NovaPeptides maintains a research-use-only position for exactly these reasons.

If you need to understand the status of a specific substance, the most reliable approach is to consult the TGA website, the ARTG and the current Poisons Standard, and to seek qualified professional advice. This article is a general explainer and is not a substitute for those sources.

Frequently asked questions